Think10

www.Think-10.com is a life science business consultancy, a personal coaching and team development to all businesses and a service to the pharmaceutical industry to facilitate change,

Melanie Lee PhD, CBE, FMedSci, DSc(Hons)

LifeArc

Chief Executive Officer

Principal CEO

BTGplc

BTG plc is a fast growing exciting Interventional Medicine company - on the international stage with it's HQ in London. We have device and drug combination products in the Interventional vascular and oncology space and have recently entered the Interventional Pulmonary area with the acquisition of PneuMRx and their innovative coiled device to treat emphysema patients. Interventional medicine routes to the market place in the hands of skilled physicians is likely to be relevant to many of the emerging new modalities in the pipelines of our innovative biotechs today.

Chief Scientific Officer

NightstaRx Ltd

NightstaRx is a Syncona backed company established to pursue the gene therapy treatment of Choroideremia to prevent the deterioration of eyesight in patients with this X-linked disease which causes loss of sight during the mid 40-50 years of life. Early clinical studies by Robert MacLaren have shown promising efficacy and good safety. The therapy for this indication is to replace the faulty REP1 gene in the eye with a functioning copy in an AAV vector. NightstaRx aims to gain regulatory approval for this therapy with ensuring GMP of the product and agreeing the pivotal clinical path. Www.nightstarx.co.uk

NED (was Founding CEO during 2014)

Syntaxin Ltd

Syntaxin was a successful biotech spun out of the HPA that was developed by myself and my management team, with the help if course of our excellent scientists, to a stage for acquisition to ensure the further investment in the recombinant botulinum toxin technology. Ipsen acquired Syntaxin in July 2013 and the site continues as Ipsen's centre for toxin engineering, complementing well the Ipsen expertise in toxin biology. I left Syntaxin with the acquisition and now work through Think10 as I discuss new opportunities.

Chief Executive officer

EVP and President UCB NewMedicines

Breast Cancer Haven

Angel

Applied Genomics Link Scheme

Working to award funds to innovate collaborative programmes between strong academic groups and small companies.

Chairman

Celltech

EVP R&D, Celltech

Glaxo

Unit Head

I'm a passionate leader dedicated to driving innovation and positive impact in the life sciences industry.🔬

Throughout my career, I have championed the translation of scientific knowledge into impactful healthcare solutions and am passionate about fostering an environment that encourages multidisciplinary collaboration, nurtures scientific talent, and supports the next generation of innovators.

I actively engage with industry leaders, policymakers, and research institutions to shape the future of the life sciences ecosystem.

By participating in conferences, thought leadership activities, and industry forums, I strive to drive positive change and advance the boundaries of medical research.

I am always excited to speak with like-minded professionals, researchers, and individuals passionate about making a difference in healthcare. ⬇️

Let's amplify our impact in healthcare by connecting and collaborating towards a brighter future.🧑🏻‍🔬

Melanie Lee

Bird & Bird

Mario is an IP and transactions specialist with extensive experience in the Life Sciences. He advises global Life Science clients on strategic IP licensing, collaboration and partnering transactions. He also supports those clients with M&A, joint ventures, asset acquisitions and disposals, strategic manufacturing, supply and outsourcing arrangements. Prior to qualifying as a solicitor, Mario worked as a research scientist in the fields of tumour immunology and molecular biology. Having spent a significant period of his career in-house advising Life Science clients, Mario brings a wealth of experience and a unique perspective to clients contemplating strategic transactions and partnerships. His experience and approach also brings great synergy to Bird & Bird's outstanding Life Sciences practice, allowing an unrivalled opportunity to support clients with their most pressing challenges.

Life Sciences Lawyer & Partner

Pinsent Masons

Mario is a Legal Director in Pinsent Masons' Tier 1 Life Sciences Team and advises life science clients on all aspects of the development and exploitation of pharmaceutical, biotech, medtech and digital health technologies. Mario specialises in negotiating strategic acquisitions, licensing, collaboration and other technology transfer arrangements, often with complex underlying technologies and international scope. 

He is recognised as a key lawyer (Legal 500) in Life Sciences in recognition of his role in advising the UK Government (Vaccine Taskforce and Antiviral & Therapeutics Taskforce) on the supply of Covid-19 vaccines and antiviral therapies and also in relation the world’s first COVID-19 human challenge study. 

Having qualifications and experience as a research scientist in the fields of immunology and molecular biology, and as in-house counsel at a number of prominent life science companies, Mario has both the technical expertise and commercial awareness to provide insightful and pragmatic advice.

Life Sciences Lawyer and Legal Director  

Anderson Law LLP

Solicitor

Syngenta

Consultant in-house counsel

Watson Pharmaceuticals (now Allergan)

Sanofi

Fasken Martineau LLP

Associate

Clifford Chance

Contract lawyer

Australian Government Solicitor

Solicitor (secondment)

Australian Securities and Investments Commission

Solicitor and Investigator

I am a partner in the Life Sciences practice at Bird & Bird, a leading international law firm with a strong focus on innovation and technology. I have over 15 years of experience in advising global clients on the development and exploitation of pharmaceutical, biotech, medtech and digital health technologies, with a particular emphasis on strategic IP licensing, collaboration, and partnering transactions.

My background includes substantial periods as a research scientist in immunology and molecular biology and as in-house counsel at several prominent Life Science companies. This gives me a unique perspective and a deep understanding of the technology and issues involved in complex and innovative transactions. 

I provide clear and pragmatic advice that aligns with my clients' business objectives and regulatory strategies. I have been recognized as a notable practitioner and a key lawyer in Life Sciences by IP Stars and Legal 500, respectively. I am proud to have contributed to the UK Government's efforts to combat the COVID-19 pandemic by advising on the purchase and deployment of COVID-19 vaccines and antiviral therapies.

Mario Subramaniam

taplio

The Battle

Melanie Lee

Mario Subramaniam

Followers

Posts

Engagements

Likes

Ready to grow your LinkedIn presence?